Mirna Therapeutics appoints Perry Nisen to its board
Dr. Nisen currently serves as the Chief Executive Officer and Donald Bren Chief Executive Chair of the Sanford Burnham Prebys Medical Discovery Institute, an independent biomedical research institute.
Before joining Sanford Burnham Prebys, Dr. Nisen served as Senior Vice President of Science and Innovation at GlaxoSmithKline (GSK), where he facilitated innovation and integration of R&D across GSK's global organization and was integral to the discovery, development, and commercialization of a vast portfolio of drugs.
Earlier in his career at GSK, he held various key positions, including interim Chief Medical Officer, Senior Vice President and Oncology Therapy Area Head, Senior Vice President of Cancer Research, and Senior Vice President of Clinical Pharmacology and Discovery Medicine.
Previously, Dr. Nisen was the Divisional Vice President of Cancer Research and Oncology Development at Abbott Laboratories.
Formerly, Dr. Nisen was the Lowe Foundation Professor of Neuro-Oncology at the University of Texas Southwestern Medical Center. He holds a B.S. from Stanford University and M.D. and Ph.D. from the Albert Einstein College of Medicine. ■
What to read next
LATEST MOVES FROM Texas
- Texas Instruments elects Brian Crutcher to board
- Integera appoints Joseph W. Dziedzic as permanent CEO
- ConocoPhillips appoints Sharmila Mulligan to board
- Summit Hotel Properties appoints Hope Taitz as independent director
- Commercial Metals appoints Barbara Smith as CEO
More inside POST
COO, a chameleon in the company Leadership